73
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Post-transcriptional regulation of the human reduced folate carrier as a novel adaptive mechanism in response to folate excess or deficiency

      research-article
      * , , 1 , * , , * , ,
      Bioscience Reports
      Portland Press Ltd.
      antifolate, folate, oligomerization, post-transcriptional regulation, reduced folate carrier, transporter, DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride, dg, deglycosylated, DSS, disuccinimidyl suberate, ER, endoplasmic reticulum, FR, folate receptor, hGAPDH, human glyceraldehyde-3-phosphate dehydrogenase, hRFC, human RFC, LCV, (6R,S)5-formyl tetrahydrofolate (leucovorin), Mtx, methotrexate, PCFT, proton-coupled folate transporter, PDI, protein disulfide isomerase, Pmx, pemetrexed, RFC, reduced folate carrier, sulfo-NHS-SS-biotin, sulfo-N-hydroxysuccinimide-SS-biotin, TMQ, trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline, UTR, untranslated region, wt, wild-type

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The RFC (reduced folate carrier) is the principal mechanism by which folates and clinically used antifolates are delivered to mammalian cells. hRFC (human RFC) is subject to complex transcriptional controls and exists as homo-oligomer. To explore the post-transcriptional regulation of hRFC by exogenous folates, hRFC-null HeLa cells were stably transfected with hRFC under control of a constitutive promoter. hRFC transcripts and the total membrane protein increased with increasing LCV [(6R,S)5-formyl tetrahydrofolate (leucovorin)] with a maximum at 20 nM LCV, attributable to reduced turnover of hRFC transcripts. hRFC homo-oligomerization was unaffected by increasing LCV. Cell surface hRFC paralleled [ 3H]methotrexate transport and increased from 0.5 to 2 nM LCV, and then decreased (~2-fold) with increasing LCV up to 20 nM. hRFC was localized to the cell surface at low LCV concentrations (0.5–1.5 nM). However, at higher LCV concentrations, significant intracellular hRFC was localized to the ER (endoplasmic reticulum), such that at 20 nM LCV, intracellular hRFC was predominated. Our results demonstrate a novel post-transcriptional regulation of hRFC involving: (i) increased hRFC transcripts and proteins, accompanying increased extracellular folates, attributable to differences in hRFC transcript stabilities; and (ii) increased retention of hRFC in the ER under conditions of folate excess, because of impaired intracellular trafficking and plasma membrane targeting.

          Abstract

          A novel regulation of the physiologically/pharmacologically important human reduced folate carrier was demonstrated in response to increasing extracellular folates, involving: (i) increased transcripts and total protein, reflecting increased transcript stabilities; and (ii) increased endoplasmic reticulum trapping, due to impaired intracellular trafficking.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Protein folding and modification in the mammalian endoplasmic reticulum.

          Analysis of the human genome reveals that approximately a third of all open reading frames code for proteins that enter the endoplasmic reticulum (ER), demonstrating the importance of this organelle for global protein maturation. The path taken by a polypeptide through the secretory pathway starts with its translocation across or into the ER membrane. It then must fold and be modified correctly in the ER before being transported via the Golgi apparatus to the cell surface or another destination. Being physically segregated from the cytosol means that the ER lumen has a distinct folding environment. It contains much of the machinery for fulfilling the task of protein production, including complex pathways for folding, assembly, modification, quality control, and recycling. Importantly, the compartmentalization means that several modifications that do not occur in the cytosol, such as glycosylation and extensive disulfide bond formation, can occur to secreted proteins to enhance their stability before their exposure to the extracellular milieu. How these various machineries interact during the normal pathway of folding and protein secretion is the subject of this review.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Folic acid: nutritional biochemistry, molecular biology, and role in disease processes.

            M Lucock (2015)
            This paper reviews the chemistry, metabolism, and molecular biology of folic acid, with a particular emphasis on how it is, or may be, involved in many disease processes. Folic acid prevents neural tube defects like spina bifida, while its ability to lower homocysteine suggests it might have a positive influence on cardiovascular disease. A role for this B vitamin in maintaining good health may, in fact, extend beyond these clinical conditions to encompass other birth defects, several types of cancer, dementia, affective disorders, Down's syndrome, and serious conditions affecting pregnancy outcome. The effect of folate in these conditions can be explained largely within the context of folate-dependent pathways leading to methionine and nucleotide biosynthesis, and genetic variability resulting from a number of common polymorphisms of folate-dependent enzymes involved in the homocysteine remethylation cycle. Allelic variants of folate genes that have a high frequency in the population, and that may play a role in disease formation include 677C --> T-MTHFR, 1298A --> C-MTHFR, 2756A --> G-MetSyn, and 66A --> G-MSR. Future work will probably uncover further polymorphisms of folate metabolism, and lead to a wider understanding of the interaction between this essential nutrient and the many genes which underpin its enzymatic utilization in a plethora of critical biosynthetic reactions, and which, under adverse nutritional conditions, may promote disease. Copyright 2000 Academic Press.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Physiology of folate and vitamin B12 in health and disease.

              Folate is a water-soluble B-vitamin and enzymatic cofactor that is necessary for the synthesis of purine and thymidine nucleotides and for the synthesis of methionine from homocysteine. Impairment of folate-mediated one-carbon metabolic pathways can result from B-vitamin deficiencies and/or single nucleotide polymorphisms, and increases risk for pathologies, including cancer and cardiovascular disease, and developmental anomalies including neural tube defects. Although several well validated metabolic and genomic biomarkers for folate deficiency exist, our understanding of the biochemical and genetic mechanisms whereby impaired folate metabolism increases risk for developmental anomalies and disease is limited, as are the mechanisms whereby elevated folate intake protects against these pathologies. Therefore, current initiatives to increase folate intakes in human populations to ameliorate developmental anomalies and prevent disease, while effective, lack predictive value with respect to unintended adverse outcomes.
                Bookmark

                Author and article information

                Journal
                Biosci Rep
                Biosci. Rep
                bsr
                BSR
                Bioscience Reports
                Portland Press Ltd.
                0144-8463
                1573-4935
                20 June 2014
                6 August 2014
                2014
                : 34
                : 4
                : e00130
                Affiliations
                *Department of Oncology Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
                †Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
                ‡Molecular Therapeutics Programme, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A.
                Author notes
                1To whom correspondence should be addressed (email houz@ 123456karmanos.org ).
                Article
                e00130
                10.1042/BSR20140065
                4122975
                24949876
                48fdd691-6797-42ee-adee-a2ad8a63be30
                © 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) ( http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 25 April 2014
                : 28 May 2014
                : 19 June 2014
                Page count
                Figures: 6, References: 37, Pages: 12
                Categories
                Original Paper
                S5

                Life sciences
                antifolate,folate,oligomerization,post-transcriptional regulation,reduced folate carrier,transporter,dapi, 4′,6-diamidino-2-phenylindole, dihydrochloride,dg, deglycosylated,dss, disuccinimidyl suberate,er, endoplasmic reticulum,fr, folate receptor,hgapdh, human glyceraldehyde-3-phosphate dehydrogenase,hrfc, human rfc,lcv, (6r,s)5-formyl tetrahydrofolate (leucovorin),mtx, methotrexate,pcft, proton-coupled folate transporter,pdi, protein disulfide isomerase,pmx, pemetrexed,rfc, reduced folate carrier,sulfo-nhs-ss-biotin, sulfo-n-hydroxysuccinimide-ss-biotin,tmq, trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline,utr, untranslated region,wt, wild-type

                Comments

                Comment on this article